Gluconorm-Z 80 Tablet is a combination oral antihyperglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea derivative, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. This dual mechanism addresses both insulin deficiency and insulin resistance, making Gluconorm-Z 80 effective in achieving optimal blood glucose levels. It is prescribed as an adjunct to diet and exercise when monotherapy with either agent is inadequate. The tablet should be taken orally with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Patients should be monitored regularly for blood glucose levels, renal function, and potential hypoglycemia, especially when initiating therapy or adjusting doses. Contraindications include renal impairment, hepatic dysfunction, and conditions predisposing to lactic acidosis. Gluconorm-Z 80 should be used cautiously in elderly patients and those with cardiovascular disease. Proper adherence to prescribed dosage and lifestyle modifications are essential to maximize therapeutic benefits and minimize adverse effects.